CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.62 USD | -0.59% |
|
+3.23% | -44.43% |
| May. 15 | Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 6.25M | Capitalization | 609M |
|---|---|---|---|---|---|
| Net income 2024 * | -108M | Net income 2025 * | -122M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 254M | Net cash position 2025 * | 173M | EV / Sales 2025 * | 69.8 x |
| P/E ratio 2024 * |
-5.97
x | P/E ratio 2025 * |
-5.66
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cabaletta Bio, Inc.
More recommendations
More press releases
| 1 day | -0.59% | ||
| 1 week | +3.23% | ||
| Current month | +18.51% | ||
| 1 month | -22.56% | ||
| 3 months | -44.82% | ||
| 6 months | -27.67% | ||
| Current year | -44.43% |
1 week
11.09
13.12
1 month
9.7515.00
Current year
9.7526.35
1 year
9.0226.35
3 years
0.5926.35
5 years
0.5926.35
10 years
0.5926.35
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 17-03-31 | |
Anup Marda
DFI | Director of Finance/CFO | 46 | 18-12-31 |
| Compliance Officer | - | 19-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 19-02-18 | |
| Chief Executive Officer | 62 | 17-03-31 | |
Mark Simon
BRD | Director/Board Member | 62 | 18-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 12.62 | -0.55% | 676,975 |
| 24-05-15 | 12.69 | +13.00% | 1,105,172 |
| 24-05-14 | 11.23 | -0.27% | 469,858 |
| 24-05-13 | 11.26 | 0.00% | 625,344 |
| 24-05-10 | 11.26 | -7.86% | 859,505 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
12.62
USD
Average target price
34
USD
Spread / Average Target
+169.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.43% | 612M | |
| +8.29% | 113B | |
| +10.21% | 106B | |
| +0.41% | 22.27B | |
| -11.90% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -5.17% | 17.24B | |
| +7.70% | 14.29B | |
| +37.65% | 12.52B |
- Stock Market
- Equities
- CABA Stock
